Home / Market News / $ARWR
fiscal.ai Corporate Catalyst Impact 55/100 ● neutral

Wall Street Analysts Update Ratings and Price Targets for Arrowhead Pharmaceuticals

Nov 15, 2026, 2:04 AM UTC · Primary ticker $ARWR

Multiple Wall Street analysts have updated their ratings and price targets for Arrowhead Pharmaceuticals. While all maintained 'buy' ratings, two firms lowered their price targets, suggesting a slightly tempered outlook despite continued bullish sentiment.

On November 14, 2026, several prominent Wall Street analysts updated their coverage of Arrowhead Pharmaceuticals. While all maintained their 'buy' ratings, Morgan Stanley and Stifel both lowered their price targets, from $120 to $106 and $104 to $96 respectively. BofA Securities, RBC Capital, and Piper Sandler maintained their 'buy' ratings, with RBC holding its target at $100 and Piper Sandler at $126. This event is moderately impactful as it reflects a consensus of continued positive sentiment but with some recalibration of valuation expectations, potentially indicating a more cautious near-term outlook or a slight de-risking of previous projections. For traders, this suggests that while the long-term bullish thesis remains, the immediate upside might be perceived as slightly less robust by some analysts, leading to potential short-term price volatility or consolidation.

$ARWR neutral Analyst price target adjustments
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.